Clinical trials: Diabetes Mellitus II
Diabetes Mellitus, Type 2
LANTUSTITR: Insulin Glargine in Type 2 Diabetes Mellitus
The rationale of the study is to determine: the first dose and the titration of basal insulin the exact daily time administration of basal insulin in poorly controlled type II diabetic patients.
- Trial name
- NCT00349986
- Testing
- Insuline glargine
- Where
- Hungary
- Volunteers
- 4 people
- Sponsor
- Sanofi
Hypoglycemia
Safety and Efficacy of a Novel Glucagon Formulation in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia
In this study, participants with Type 1 diabetes received insulin through an infusion into a vein to reduce their blood glucose, and then received nasal glucagon (NG) or glucagon for injection under the skin, and their blood…
- Trial name
- AMG102 (NCT01556594)
- Testing
- Nasal Glucagon 1 mg, Nasal Glucagon 2 mg, SC Glucagon
- Where
- Canada
- Volunteers
- 18 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes
This study is a phase 3b, multicentre, randomised, open label, parallel group study. A 4-week run-in period will be followed by a median of 6 years of treatment with study medication in addition to continuation of background…
- Trial name
- RECORD (NCT00379769)
- Testing
- Rosiglitazone, Sulfonylurea, Metformin
- Where
- 446 sites in Australia, Belgium and 23 more
- Volunteers
- 4,447 people
- Sponsor
- GlaxoSmithKline
Diabetic Foot Ulcers
A Clinical Study of the Safety and Efficacy of MEBO® Wound Ointment in Subjects With Diabetic Foot Ulcers (Pilot)
The objective of this study is to evaluate the safety and efficacy of MEBO in the treatment of subjects with diabetic foot ulcers (DFUs).
- Trial name
- NCT01154374
- Testing
- MEBO Wound Ointment, Standard of Care (sterile saline moistened gauze)
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Skingenix, Inc.
Type2 Diabetes Mellitus
A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)
The objectives of the study is to evaluate the efficacy, safety, and dose of DS-8500a compared with placebo in patients with type 2 diabetes mellitus.
- Trial name
- NCT02628392
- Testing
- DS-8500a, Sitagliptin
- Where
- Japan
- Volunteers
- 368 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Type II Diabetes
Clinical Trial to Investigate the Pharmacokinetics and Safety After Oral Administration of CKD-378 and Co-administration of D745, D150, D029 in Healthy Adults
A clinical trial to compare and evaluate the safety and pharmacokinetics of CKD-378
- Trial name
- CKD-378 (NCT05881213)
- Testing
- CKD-378 (low-dose)
- Where
- South Korea
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Type 2 Diabetes Mellitus
MK-0431 Early Phase II Double-blind Study - Type 2 Diabetes Mellitus (0431-043)
A clinical study to determine the safety and efficacy of MK-0431 in patients with Type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy
- Trial name
- NCT00371007
- Testing
- MK0431, sitagliptin phosphate / Duration of Treatment: 12 Weeks
- Volunteers
- 126 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)
The objective of this trial is to evaluate the pharmacodynamics, pharmacokinetics, safety, and tolerability of once daily oral administration of BI 10773 administered for 28 days in Japanese patients with T2DM.
- Trial name
- NCT00885118
- Testing
- BI 10773
- Where
- 5 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Study To Evaluate The Safety And Efficacy Of An Investigational Diabetes Drug In Poorly Controlled Type II Diabetics
The purpose of this research study is to determine if a new investigational diabetes drug is safe and effective in treating people who have Type II diabetes mellitus with very high HbA1c or FPG (fasting plasma glucose) levels.
- Trial name
- NCT00067951
- Testing
- rosiglitazone/metformin
- Where
- 94 sites in United States, Australia and 3 more
- Volunteers
- 190 people
- Sponsor
- GlaxoSmithKline
T2DM (Type 2 Diabetes Mellitus)
A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus
This randomized, double-blind, placebo-controlled Phase II study is designed to evaluate the efficacy, safety, and tolerability of ASC30 oral tablets formulation in participants with Type 2 Diabetes Mellitus
- Trial name
- NCT07321678
- Testing
- ASC30 tablets
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- Ascletis Pharma (China) Co., Limited
Diabetes in Adolescence, PreDiabetes
The Efficacy of AP029 Mix in Patients With Impaired Carbohydrate Metabolism
The aim of the study is to demonstrate that a daily supplementation of AP029 Mix: I) has a positive effect on reducing side effects of metformin, while enhancing the therapeutic effect of metformin; II) normalizes prediabetes…
- Trial name
- NCT05994586
- Testing
- AP029 mix
- Where
- Poland
- Volunteers
- 30 people
- Sponsor
- AronPharma Sp. z o. o.
Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis
Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver
This randomized clinical trial aims to compare the effect of the pioglitazone and SGLT2 inhibitor combination on liver fat mass, as compared to either drug used alone, with or without background medical therapy of metformin…
- Conditions
- Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis, NAFLD
- Trial name
- NCT04976283
- Testing
- Pioglitazone, Empagliflozin, Pioglitazone + Empagliflozin
- Where
- Pakistan
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- Getz Pharma
Overweight or Obese Participants Without Diabetes
A Study to Evaluate Efficacy and Safety of BGM0504 Tablets in Overweight or Obese Participants Without Diabetes
To evaluate the efficacy of BGM0504 tablets compared with placebo in reducing body weight in overweight or obese participants without diabetes after 20 weeks of treatment.
- Trial name
- NCT07658560
- Testing
- BGM0504 tablets
- Where
- China
- Volunteers
- 200 people
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Diabetes Mellitus, Type II
A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.5/1000 mg in Healthy Male Volunteers
This study is a randomized, open-label, single dose, 2-way crossover study to compare the pharmacokinetic characteristics of CKD-395 0.5/1000 mg in healthy male volunteers.
- Trial name
- NCT02565368
- Testing
- Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mg, CKD-395 0.5/1000mg
- Where
- South Korea
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Diabetes Mellitus, Type 2
The TANTALUS® II for the Treatment of Type 2 Diabetes
Evaluation of the safety and efficacy of gastric contractility modulation (GCM) stimulation using the TANTALUS System in the improvement of glycemic control measured by changes in HbA1c.
- Trial name
- Crossover (NCT01303302)
- Testing
- Tantalus System
- Where
- 7 sites in Austria, Germany and 2 more
- Volunteers
- 51 people
- Sponsor
- MetaCure (USA), Inc.
Diabetes Mellitus, Type 2, Healthy
Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls
Single center, 14-day, open-label trial to examine the effect of 25 mg q.d. empagliflozin on kinetics of renal glucose reabsorption in patients diagnosed with type 2 diabetes mellitus and healthy controls
- Trial name
- NCT01867307
- Testing
- Empagliflozin, BI 10773
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Neuropathic Pain, Diabetes Mellitus, Type 2
A Randomized, Active-controlled, Parallel, Open-label, Multicenter, Phase 4 Study to Compare the Efficacy and Safety of Pregabalin Sustained Release Tablet and Pregabalin Immediate Release Capsule in Type II Diabetic Patients With Peripheral Neuropathic Pain
This study is to compare the efficacy and safety of pregabalin sustained release tablet and pregabalin immediate release capsule in type II diabetic patients with peripheral neuropathic pain.
- Trial name
- NCT05624853
- Testing
- pregabalin sustained release tablet, pregabalin immediate release capsule
- Where
- 8 sites in South Korea
- Volunteers
- 130 people
- Sponsor
- Yuhan Corporation
Hypertension, Diabetes Mellitus, Type II
Phase 4 Study to Assess the Effect of Bisoprolol on Glycemic Level in Type II Diabetic Subjects With Suboptimal Blood Pressure Control
This is a 24-week, prospective, multicenter, open-label, single-arm study to assess the effect of bisoprolol on glycemic level in Type 2 diabetes mellitus (T2DM) controlled subjects with hypertension.
- Trial name
- GIANT (NCT01066039)
- Testing
- Bisoprolol
- Where
- South Korea
- Volunteers
- 202 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Diabetes Mellitus, Type 2
An Open Study to Evaluate Whether Pack Size Affects Compliance of Metformin Treatment in Subjects With Type II Diabetes
MTF116086 is an open-label, randomised, parallel-design study in subjects with type II diabetes. The study is site-based, with local pharmacies serving as the sites and pharmacists as principal investigators for the sites.
- Trial name
- NCT01817777
- Testing
- Metformin Small Pack, Metformin Large Pack
- Where
- 7 sites in Argentina
- Volunteers
- 31 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
Safety, Tolerance and Activity of HE3286 in Patients With Type 2 Diabetes Mellitus
This is a phase II, double-blind, randomized, placebo-controlled study of the safety, tolerance and activity of HE3286 in patients with type 2 diabetes mellitus.
- Trial name
- NCT00694057
- Testing
- HE3286
- Where
- 22 sites in United States
- Volunteers
- 164 people
- Sponsor
- Harbor Therapeutics